Allergy/Imm

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chang DY et al. - These immune-based therapies for chronic HCV infection include therapeutic vaccines, antagonists of T cell inhibitory factors, anti-HCV neutralizing antibodies, cytokines, and agonists for TLRs. Currently, various types of immune-based therapies are under development that might be used as a monotherapy or in combination with other antiviral drugs for the treatment of chronic HCV infection.

Related Articles

Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany
Journal of Clinical Virology, 11/16/09    Relevance Score: 91%

Liver enzyme abnormalities in systemic lupus erythematosus: A focus on toxic hepatitis
Rheumatology International, 11/13/09    Relevance Score: 91%

De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation
Liver Transplantation, 10/30/09    Relevance Score: 91%

Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression
Clinical Gastroenterology and Hepatology, 10/09/09    Relevance Score: 91%

FOXP3 Expression in Hepatitis C Virus-Specific CD4+ T Cells During Acute Hepatitis C
Gastroenterology, 10/06/09    Relevance Score: 91%

Today in Gastrointestinal/Hepatic...keeping you current

Clinical factors predicting disease course in Crohn's disease
Expert Review of Clinical Immunology, 12/17/09

Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses
Immunology & Cell Biology, 12/17/09

Mucosally induced Immunological Tolerance, Regulatory T Cells and the Adjuvant Effect by Cholera Toxin B Subunit
Scandinavian Journal of Immunology, 12/16/09

Today in Vaccine/Immunotherapy...keeping you current

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
New England Journal of Medicine, 12/17/09

A Novel Influenza A (H1N1) Vaccine in Various Age Groups
New England Journal of Medicine, 12/17/09

Efficacy and Safety of Pentavalent Human-Bovine Reassortant Rotavirus Vaccine When Administered With Greater Than 10 Weeks Between Doses
The Pediatric Infectious Disease Journal, 12/17/09